Literature DB >> 11287676

Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation.

K Lindauer1, T Loerting, K R Liedl, R T Kroemer.   

Abstract

The structure of human Janus kinase 2 (JAK2) comprising the two C-terminal domains (JH1 and JH2) was predicted by application of homology modelling techniques. JH1 and JH2 represent the tyrosine kinase and tyrosine kinase-like domains, respectively, and are crucial for function and regulation of the protein. A comparison between the structures of the two domains is made and structural differences are highlighted. Prediction of the relative orientation of JH1 and JH2 was aided by a newly developed method for the detection of correlated amino acid mutations. Analysis of the interactions between the two domains led to a model for the regulatory effect of JH2 on JH1. The predictions are consistent with available experimental data on JAK2 or related proteins and provide an explanation for inhibition of JH1 tyrosine kinase activity by the adjacent JH2 domain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287676     DOI: 10.1093/protein/14.1.27

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  52 in total

1.  Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.

Authors:  Anurima Majumder; Lakshmanan Govindasamy; Andrew Magis; Róbert Kiss; Tímea Polgár; Rebekah Baskin; Robert W Allan; Mavis Agbandje-McKenna; Gary W Reuther; György M Keseru; Kirpal S Bisht; Peter P Sayeski
Journal:  J Biol Chem       Date:  2010-07-28       Impact factor: 5.157

2.  Activation of JAK2-V617F by components of heterodimeric cytokine receptors.

Authors:  Anuradha Pradhan; Que T Lambert; Lori N Griner; Gary W Reuther
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

3.  Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.

Authors:  Geoff M Gordon; Que T Lambert; Kenyon G Daniel; Gary W Reuther
Journal:  Biochem J       Date:  2010-12-01       Impact factor: 3.857

4.  Development of a quantitative real-time polymerase chain reaction assay for the detection of the JAK2 V617F mutation.

Authors:  Elizabeth C Wolstencroft; Katy Hanlon; Lorna W Harries; Graham R Standen; Alexander Sternberg; Sian Ellard
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

Review 5.  The molecular mechanisms that control thrombopoiesis.

Authors:  Kenneth Kaushansky
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 6.  JAK2 inhibitors: what's the true therapeutic potential?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Blood Rev       Date:  2010-11-20       Impact factor: 8.250

7.  Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

Authors:  Xiaohui Lu; Ross Levine; Wei Tong; Gerlinde Wernig; Yana Pikman; Sara Zarnegar; D Gary Gilliland; Harvey Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 8.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

9.  JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.

Authors:  Alexandra Dusa; Céline Mouton; Christian Pecquet; Murielle Herman; Stefan N Constantinescu
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

10.  The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice.

Authors:  Megumi Funakoshi-Tago; Kenji Tago; Kazuya Sumi; Miyuki Abe; Eriko Aizu-Yokota; Tomoyuki Oshio; Yoshiko Sonoda; Tadashi Kasahara
Journal:  J Biol Chem       Date:  2009-03-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.